T cells are a type of white blood cell that plays an important role in protecting the body from infections. These cells can identify, attack and destroy infectious agents directly which include cancer cells. In cancer patients, the cancer cells often develop protective mechanisms to avoid being recognized by T cells. CAR-T cell therapy uses the patient's own T cells which are genetically modified in the laboratory to target and kill cancer cells. CAR-T cell therapy has been approved by FDA/HSA for the treatment of relapsed refractory haematological malignancies including Acute lymphoblastic leukaemia, B cell lymphomas and multiple myeloma.